A synthetic prostate tetrapeptide with no validated human dose. What research-chem sources report for short courses, plus the extract-vs-synthetic caveat.
Prostamax is a synthetic prostate tetrapeptide (Lys-Glu-Asp-Pro, or KEDP) from the Khavinson family of peptide bioregulators, and it has no validated human dose. Research-chemical vendors and self-reported community sources most commonly describe 20mg lyophilized vials reconstituted and administered as short subcutaneous or intramuscular courses of roughly 10-20 days, with daily amounts community-reported around 1-2mg — following the Russian bioregulator "course" convention rather than continuous daily use.
Every number below comes from vendor labeling and self-reported community sources, not from clinical dose-finding trials. One distinction drives the whole page: the prostate clinical record usually invoked for "prostate peptides" belongs to Prostatilen, the injectable prostate polypeptide extract, not to synthetic Prostamax — and the synthetic tetrapeptide's only verified study looked at chromatin and cellular aging, not prostate disease.
Research-context information only. Prostamax is a research peptide. Protocols, doses, and reactions reported below come from published research and self-reported community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.
Prostamax is a synthetic short-chain bioregulator modeled on a fragment associated with the Prostatilen prostate extract. This guide reports the reconstitution math, the course-length convention, and the provenance of those figures.
Quick Reference: Protocol
The table below reports community and vendor-documented figures. Because no clinical dose-finding study exists for the synthetic peptide, none of these values represent a standard or validated protocol.
Parameter
Community / Research-Chem-Reported
Dose
~1-2mg per administration (self-reported; no validated human dose)
Route
Subcutaneous or intramuscular injection
Timing
Once daily, community-reported
Frequency
Daily across a short course
Course length
~10-20 days per course (Russian bioregulator convention)
Vial size
Commonly 20mg lyophilized research vials
Reconstitution
Bacteriostatic water → see table below
Storage
Refrigerate reconstituted vial, use within 28 days
These figures describe how research-chemical sources and community references document the compound. They are self-reported, not a clinically established schedule.
Routes of Administration
Self-reported community protocols describe two injection routes for the reconstituted synthetic peptide:
Subcutaneous (SC): the most commonly described route in community sources, using a small insulin syringe into subcutaneous tissue.
Intramuscular (IM): also reported; the parent extract Prostatilen is administered intramuscularly (or rectally as a suppository) in its clinical setting, and some community references carry the injectable convention over to the synthetic.
No route has been validated for synthetic Prostamax. Vendors sell it labeled for laboratory research only, not for human use.
Bac Water Made for Peptides
Don't risk a $300 peptide on generic bac water.
Most cloudy reconstitutions trace back to one thing — and it isn't the peptide. Sterile, non-pyrogenic, 0.9% benzyl alcohol — formulated for peptide reconstitution, not repackaged from generic stock.
✓ 0.9% benzyl alcohol✓ Made for peptides✓ 30 mL multi-dose
30ml from $18.75 · Ships fast · Code thepeptidecatalog
Reconstitution Quick Reference
Vial Size
BAC Water
Concentration
1mg Draw
20mg
2mL
10mg/mL
0.1mL (~10 units)
The math: a 20mg vial plus 2mL of bacteriostatic water yields 10mg/mL, so a 1mg amount is 0.1mL, or roughly 10 units on a U-100 insulin syringe. Community notes describe swirling gently rather than shaking, refrigerating at 2-8°C, and discarding after 28 days.
There is no clinical dose-finding trial for synthetic Prostamax, so the figures above are not derived from established human data. The dose amounts and course lengths circulating in community sources are inherited from the Russian bioregulator tradition — the short, repeatable "course" convention originally applied to injectable tissue extracts — rather than from a study that titrated the synthetic tetrapeptide in people.
The evidence that exists for the synthetic molecule is thin. The one verified study of the Lys-Glu-Asp-Pro peptide examined chromatin structure and markers of cellular aging in cultured cells, not prostate function or prostate disease (23221144). That is the originators' in-vitro finding about a proposed gene-regulatory mechanism, not evidence that injected Prostamax does anything for the prostate in humans. Independent Western replication is effectively absent.
The proposed mechanism is Khavinson's gene-expression hypothesis — the idea that very short peptides interact with DNA and chromatin to modulate transcription — a model demonstrated largely in vitro rather than in human tissue (23221144). Whether it explains any effect of injected Prostamax in people has not been established.
The most important caveat for anyone reading dosing claims: the prostate clinical record usually cited for "prostate peptides" belongs to Prostatilen (also marketed as Vitaprost), the injectable prostate polypeptide extract used in Russian urology, and not to the synthetic Prostamax research chemical. Extract and synthetic are different products with different evidence bases. Clinical figures documented for the extract should not be read as validated for the synthetic peptide, and synthetic Prostamax has not been shown to treat prostatitis or benign prostatic hyperplasia.
Stacking Protocols
Community references sometimes describe running Prostamax alongside other Khavinson-family short peptides as part of a broader bioregulator course. These combinations are self-reported and carry no trial support.
What dose of Prostamax do research-chemical sources report?
There is no validated human dose. Vendor labeling and self-reported community sources most commonly describe 20mg lyophilized vials reconstituted and given as short subcutaneous or intramuscular courses of roughly 10-20 days, with daily amounts community-reported around 1-2mg. These are self-reported figures, not a clinically established protocol.
How long is a Prostamax course, per community sources?
Self-reported community protocols and the Russian bioregulator convention describe short courses of about 10-20 days rather than continuous daily use, sometimes repeated after a break. This course-and-pause pattern reflects how the prostate tissue extract Prostatilen has historically been administered, not a validated schedule for the synthetic peptide.
Is the human data on Prostamax from the synthetic peptide or the extract?
The prostate clinical record belongs to Prostatilen (also sold as Vitaprost), the injectable prostate polypeptide extract, not to synthetic Prostamax. The synthetic tetrapeptide (Lys-Glu-Asp-Pro) has only a small preclinical literature, and its one verified study looked at chromatin and aging, not prostate outcomes. Synthetic Prostamax has not been shown to treat prostatitis or benign prostatic hyperplasia.
How is Prostamax reconstituted, per documented protocols?
Community reconstitution notes describe adding 2mL of bacteriostatic water to a 20mg vial for a 10mg/mL concentration, where a 1mg amount equals 0.1mL or roughly 10 units on a U-100 insulin syringe. The reconstituted vial is refrigerated and typically discarded after 28 days. These figures report the math community sources document, not a recommended schedule.
What route do community sources use for Prostamax?
Self-reported community protocols describe subcutaneous or intramuscular injection of the reconstituted synthetic peptide. The Prostatilen extract is administered intramuscularly or rectally in its clinical setting. No route has been validated for the synthetic research chemical, which is sold labeled for laboratory research only.
